Sema4 Strengthens AI-Driven Genomic, Clinical Data Platform With $623M GeneDx Acquisition

Sema4 Holdings Corp SMFR has agreed to acquire OPKO Health Inc's OPK wholly-owned subsidiary, GeneDx Inc, for approximately $623 million.

  • Sema4 will acquire GeneDx for an upfront payment of $150 million in cash plus 80 million shares in Sema4, with up to an additional $150 million revenue-based milestones over the next two years.
  • Together, Sema4 and GeneDx will be one of the largest providers of genomic clinical testing in the U.S., with a projected $350 million in pro forma 2022 revenue.
  • Katherine Stueland, President and CEO of GeneDx, will be appointed as Sema4 co-CEO and board member.
  • In conjunction with the transaction, board member Jason Ryan will assume the role of Executive Chair of Sema4's board. 
  • As part of the transaction, Sema4 has also announced a $200 million private placement at $4/share from a syndicate of institutional investors, including Pfizer Inc PFE
  • The acquisition and the private placement are expected to close in Q2 2022.
  • Sema4 expects FY22 sales of $215 million - $225 million, implying 23-29% growth excluding revenue associated with COVID-19.
  • Sema4 also expects to result over 350,000 tests in 2022, excluding COVID-19 tests. 
  • In December, Sema4 decided to discontinue COVID-19 testing services by March 31, 2022. 
  • The company held cash and equivalents of approximately $400 million as of December 31, 2021.
  • Price Action: SMFR shares are down 4.58% at $3.86, and OPK is up 1.77% at $4.61 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsM&ANewsPenny StocksGuidanceHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!